Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...

Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated ...

Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, ...

Le 17 novembre 2025, Rigel Pharmaceuticals, Inc. a annoncé la publication, après évaluation par des pairs, des données finales sur cinq ans issues de la cohorte pivot de l'essai ...

NeOnc Technologies Holdings, Inc. a annoncé avoir terminé l'inclusion de l'ensemble des patients dans son essai clinique de ...

NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”) , a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today ...

Servier today announced that it will present new and updated data from its neuro-oncology program at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19 – 23 in Honolulu, ...

Glioblastoma-the most aggressive form of brain cancer-remains one of medicine's biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most patients survive only about a year after ...

This milestone follows the Company’s recent announcement of positive results from a 24-patient cohort treated with NEO100. The findings were presented to the investment community during NeOnc’s ...

Isocitrate lyase (ICL) plays a pivotal role in the persistence of Mycobacterium tuberculosis in mice by sustaining intracellular infection in inflammatory macrophages. The enzyme allows net carbon ...

A new study reveals that impaired brain fluid flow in regions opposite the tumor predicts shorter survival in glioblastoma, ...